Phase I Trial of Afatinib in Pediatric Tumours

Status: Recruiting
DFCI Protocol ID: 15-315

Open-label, dose escalation, monotherapy, basket trial with biomarker specific MTD expansion cohort The trial will consist of 2 parts: 1. Dose finding part to determine the MTD 2. Biomarker specific MTD expansion cohort to assess clinical anti-tumour activity in included tumour types

Conducting Institutions:

Children's Hospital Boston, Dana-Farber Cancer Institute

Overall PI:

Mark Kieran, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:


Dana-Farber Cancer Institute: Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP,

Eligibility Criteria

Inclusion criteria:

  -  Paediatric patients aged 2 years to <18 years at the time of informed consent

  -  diagnosis of HGG, DIPG, low grade astrocytoma, medulloblastoma/PNET, ependymoma,
     neuroblastoma, RMS and tumours with ErbB deregulation

  -  recurrent/refractory disease after they received at least one prior standard
     treatment regimen

  -  no effective conventional therapy exists

  -  Performance status >= 50% (Lansky for =<12ys; Karnofsky for >12ys)

Exclusion criteria:

  -  relevant toxicity from previous treatment

  -  known pre-existing relevant cardiac , hepatic, renal, bone marrow dysfunction, ILD,

Know Your Options

Not sure which clinical trials might be right for your child? Email our clinical trials team at
We can help you navigate your options.

Get Clinical Trial Updates


Stay informed about Dana-Farber/Boston Children's research efforts, including information on new and current clinical trials. Sign up to receive our email newsletter Advances in Pediatric Hematology/Oncology.